Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
JNCI Journal of the National Cancer Institute (2018) Vol. 111, Iss. 1, pp. 86-94
Open Access | Times Cited: 84

Showing 26-50 of 84 citing articles:

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Matteo Lambertini, François Richard, Bastien Nguyen, et al.
Clinical Medicine Insights Reproductive Health (2019) Vol. 13
Open Access | Times Cited: 30
How to Protect Ovarian Function before and during Chemotherapy?
Luca Arecco, Tommaso Ruelle, Valentino Martelli, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4192-4192
Open Access | Times Cited: 24
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer
Rayan Kabirian, Maria Alice Franzoi, Julie Havas, et al.
JAMA Network Open (2023) Vol. 6, Iss. 11, pp. e2343910-e2343910
Open Access | Times Cited: 9
Menstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment
Mariana Robalo Cordeiro, Ricardo Roque, Bárbara Laranjeiro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8468-8468
Open Access | Times Cited: 3
Sp1‐mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2‐overexpressing breast cancer
Guoyin Li, Qiaosheng Xie, Zhiwei Yang, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 12, pp. 3285-3298
Open Access | Times Cited: 29
Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation
Wanyuan Cui, Prudence A. Francis, Sherene Loi, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 113, Iss. 12, pp. 1770-1778
Open Access | Times Cited: 21
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer
Philip D. Poorvu, Jiani Hu, Yue Zheng, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 20
Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue
Matteo Lambertini, Camilla Marrocco, Stefano Spinaci, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 7
Open Access | Times Cited: 15
Optimizing treatment for HER2-positive HR-positive breast cancer
Véronique Debien, Evandro de Azambuja, Martine Piccart
Cancer Treatment Reviews (2023) Vol. 115, pp. 102529-102529
Closed Access | Times Cited: 8
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients
Luca Arecco, Marta Perachino, Alessandra Damassi, et al.
Breast Cancer Basic and Clinical Research (2020) Vol. 14
Open Access | Times Cited: 21
Impact of Systemic Therapy on Fertility in Women with Early-Stage Breast Cancer
Kelsey Natsuhara, A. Jo Chien
Current Breast Cancer Reports (2024) Vol. 16, Iss. 1, pp. 61-68
Open Access | Times Cited: 2
Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Lights and Shadows
Meredith M. Regan, Gini F. Fleming, Barbara Walley, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 11, pp. 862-866
Open Access | Times Cited: 22
The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis
Shibin Cai, Wen‐Jia Zuo, Xun‐Xi Lu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 17
Breast cancer treatment and ovarian function
Şule Yıldız, Gamze Bildik, Can Benlioğlu, et al.
Reproductive BioMedicine Online (2022) Vol. 46, Iss. 2, pp. 313-331
Open Access | Times Cited: 10
The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence
Chuqing Wu, Tong Wu, Dan Chen, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 10
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs
Elena Lorenzi, Matteo Simonelli, Pasquale Persico, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 5, pp. 503-521
Closed Access | Times Cited: 13
Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction
Parker L. Bussies, Elliott G. Richards, Seth J. Rotz, et al.
Reproductive BioMedicine Online (2021) Vol. 44, Iss. 1, pp. 81-92
Closed Access | Times Cited: 13
Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
Valentino Martelli, Maria Maddalena Latocca, Tommaso Ruelle, et al.
Breast Cancer Targets and Therapy (2021) Vol. Volume 13, pp. 341-351
Open Access | Times Cited: 11
A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer
Lukas Sollfrank, SC Linn, Michael Hauptmann, et al.
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer
Luca Arecco, Roberto Borea, Isotta Martha Magaton, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 9, pp. 803-817
Closed Access | Times Cited: 1
Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations
Perminder S. Sachdev, N. Ayad, Constantina Constantinou
Current Oncology Reports (2024)
Closed Access | Times Cited: 1
HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
Shuai Li, Jiayi Wu, Ou Huang, et al.
The Breast (2020) Vol. 54, pp. 235-241
Open Access | Times Cited: 11
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
Chiara Molinelli, Francesca Parisi, Maria Grazia Razeti, et al.
Expert Review of Anticancer Therapy (2020) Vol. 21, Iss. 3, pp. 241-250
Closed Access | Times Cited: 11
Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients
Yael Shulman, Benny Almog, Yael Kalma, et al.
Journal of Assisted Reproduction and Genetics (2021) Vol. 38, Iss. 3, pp. 743-750
Open Access | Times Cited: 10
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 10

Scroll to top